ROCHE MUST DIVEST EUROPEAN COBAS MIRA CHEMISTRY ANALYZER BUSINESS UNDER CORANGE MERGER, EU SAYS; COMMISSION ALSO ORDERS LIBERALIZED PCR LICENSING
This article was originally published in The Gray Sheet
Roche will have to divest its European Cobas Mira clinical chemistry business and liberalize its licensing of polymerase chain reaction technology to proceed with its acquisition of Corange Group companies Boehringer Mannheim and DePuy, the European Commission decided Feb. 4.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.